DS8201-854 GOG-3122 (DESTINY_Endometrial02): A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

Objective

Clinical Trial Details

Principal Investigator(s)

David Starks, MD

Clinical Trial Categories

• Cancer
• Gynecologic Cancer

Contact

Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org